The large capital raise signals extended runway for clinical development but introduces substantial near-term dilution. The 40% conversion premium suggests management confidence in future stock appreciation, but the size of the offering, combined with recent insider selling, may pressure shares short-term. Traders should monitor use of proceeds and clinical trial milestones as forward catalysts.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $152.54entry
- T+1 · 7mo ago −2.14%α −2.40% · $149.27
- T+5 · 7mo ago −7.24%α −8.88% · $141.50
- T+20 · 6mo ago −4.47%α −10.51% · $145.72
- T+60 · 4mo ago +22.51%α +14.38% · $186.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common stock at $142.00 per share, raising $1.5B gross, and $500M in 0.50% convertible senior notes due 2033, increasing both offerings from previously announced sizes. Net proceeds are expected to total approximately $1.92B ($1.435B from stock, $486.8M from notes), to be used for R&D, commercialization, and general corporate purposes.
Key Financial Metrics
Key Facts
- Priced concurrent offerings: $1.5B common stock offering and $500M convertible note offering
- Common stock priced at $142.00 per share; 10,563,381 shares issued
- Convertible notes have 0.50% coupon, mature May 1, 2033, with $500M principal
- Offering sizes increased from initial $750M (stock) and $250M (notes)
- Underwriters granted 30-day option to purchase up to 1,584,506 additional shares
- Initial conversion price for notes: ~$198.80 per share (40% premium to stock offering price)
- Net proceeds estimated at $1.435B (stock) and $486.8M (notes), totaling ~$1.92B
- Proceeds to fund R&D, commercialization, and general corporate expenses
- Recent insider selling: $3.1M across 8 transactions in past 30 days
Financial Impact
Approximately $1.92B in net proceeds, but significant dilution from equity raise and potential conversion of notes
Risk Factors
- Significant equity dilution from $1.5B common stock offering
- Potential for future share overhang if convertible notes are equity-settled
- Market may interpret large capital raise as lack of confidence in near-term commercial viability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274107 |
Track record
44 reports on RVMD
7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers